Advanced

Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study

Ullman, A; Löfdahl, Claes-Göran LU ; Melander, B and Svedmyr, N (1996) In Allergy 51(10). p.745-748
Abstract
Formoterol administered by a dry-powder (DP) capsule inhaler was compared with a pressurized metered-dose inhaler (pMDI) with regard to bronchodilating and systemic effects. The study used a double-blind, crossover, double-dummy technique. Twelve patients with moderate reversible asthma in a stable phase were examined on two separate study days, and the inhalers were given in randomized order. After baseline measurements, increasing doses of formoterol were given at intervals of 75 min. FEV1 and heart rate and tremor measurements were repeated after each dose, and the doses were 12 + 12 + 24 + 48 micrograms, giving a total dose of 96 micrograms. The peak expiratory flow rate (PEFR) was recorded in the morning before the first dose, after... (More)
Formoterol administered by a dry-powder (DP) capsule inhaler was compared with a pressurized metered-dose inhaler (pMDI) with regard to bronchodilating and systemic effects. The study used a double-blind, crossover, double-dummy technique. Twelve patients with moderate reversible asthma in a stable phase were examined on two separate study days, and the inhalers were given in randomized order. After baseline measurements, increasing doses of formoterol were given at intervals of 75 min. FEV1 and heart rate and tremor measurements were repeated after each dose, and the doses were 12 + 12 + 24 + 48 micrograms, giving a total dose of 96 micrograms. The peak expiratory flow rate (PEFR) was recorded in the morning before the first dose, after the last dose, and then repeatedly at home until 19 h after the last dose. There was an equal increase in ventilatory capacity at each dose level, independent of inhaler device. Repeated PEFR measurements after the last dose did not reveal any differences in duration of effect. There was a slight but statistically significant increase in heart rate and tremor after the highest doses of the DP formulation compared to the pMDI. These systemic effects can probably be explained by the reduced oral deposition of the aerosol caused by using a spacer. This study indicates that the DP and pMDI formulations of formoterol are equipotent in bronchodilation. (Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
β2, -agonist, bronchial asthma, cumulative, dose-response, dry powder, formoterol
in
Allergy
volume
51
issue
10
pages
745 - 748
publisher
Wiley-Blackwell
external identifiers
  • pmid:8905004
  • scopus:0029808987
ISSN
1398-9995
DOI
10.1111/j.1398-9995.1996.tb04457.x
language
English
LU publication?
no
id
18871eca-e15c-41c1-ad30-1ed4abedb143 (old id 1110630)
date added to LUP
2008-07-30 09:23:05
date last changed
2017-01-01 07:07:38
@article{18871eca-e15c-41c1-ad30-1ed4abedb143,
  abstract     = {Formoterol administered by a dry-powder (DP) capsule inhaler was compared with a pressurized metered-dose inhaler (pMDI) with regard to bronchodilating and systemic effects. The study used a double-blind, crossover, double-dummy technique. Twelve patients with moderate reversible asthma in a stable phase were examined on two separate study days, and the inhalers were given in randomized order. After baseline measurements, increasing doses of formoterol were given at intervals of 75 min. FEV1 and heart rate and tremor measurements were repeated after each dose, and the doses were 12 + 12 + 24 + 48 micrograms, giving a total dose of 96 micrograms. The peak expiratory flow rate (PEFR) was recorded in the morning before the first dose, after the last dose, and then repeatedly at home until 19 h after the last dose. There was an equal increase in ventilatory capacity at each dose level, independent of inhaler device. Repeated PEFR measurements after the last dose did not reveal any differences in duration of effect. There was a slight but statistically significant increase in heart rate and tremor after the highest doses of the DP formulation compared to the pMDI. These systemic effects can probably be explained by the reduced oral deposition of the aerosol caused by using a spacer. This study indicates that the DP and pMDI formulations of formoterol are equipotent in bronchodilation.},
  author       = {Ullman, A and Löfdahl, Claes-Göran and Melander, B and Svedmyr, N},
  issn         = {1398-9995},
  keyword      = {β2,-agonist,bronchial asthma,cumulative,dose-response,dry powder,formoterol},
  language     = {eng},
  number       = {10},
  pages        = {745--748},
  publisher    = {Wiley-Blackwell},
  series       = {Allergy},
  title        = {Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study},
  url          = {http://dx.doi.org/10.1111/j.1398-9995.1996.tb04457.x},
  volume       = {51},
  year         = {1996},
}